IN THE STUDY Clause Examples for Any Agreement

IN THE STUDY. While on the study, the risks are: • Loss of Confidentiality: Every precaution will be taken to remove identifying information from all data taken for this study, but absolute assurance of confidentiality cannot be given.
Source 1Source 2Source 3
IN THE STUDY. This consent form contains important information to help you decide if you want to be in the study. If you have any questions that are not answered in this consent form, ask one of the study staff. Please answer YES or NO to the following questions:
Source 1Source 2
IN THE STUDY. You may receive up to for being in the study. You will be paid per completed visit as follows: Screening Visit 1 Visit 2 Visit 3 Follow-up Telephone Call Total compensation for study completion will be up to for completion of all study visits and the
Source 1
IN THE STUDY. You might feel tired from the eye exams or study procedures. Also, the eye exams and measurements may pose risks because some devices come very close to or touch your eyes. There is a small chance that the instrument used could scratch the surface of your eye. If that occurs, it is usually minor. Also, you may experience blurred vision or discomfort from the numbing drop that the study doctor gives you. These could last up to 24 hours after the exam. Also, there is a risk of allergic reaction (itching, redness, burning, or mucous discharge) to the ingredients in the anesthetic (numbing) eye drop used in these evaluations. If experienced, this could last up to 12 hours. Because your eyes are numb, it’s important that you do not rub your eyes for at least 20 minutes after the exam. The orange-yellow (Fluorescein) dye that will be put in your eyes to evaluate the intraocular pressure (pressure inside your eye) may make your skin and bodily secretions and excretions, such as your tears or mucous, change color, or they may cause some irritation to your eyes. This effect is usually temporary and disappears within a day. Rarely, people can have an allergic reaction to fluorescein dye. This would usually involve itching, swelling, or redness. If you develop such a reaction, you will receive treatment. As with any allergy, more serious or life threatening reactions are possible. No adverse reactions (bad side effects) have been reported for the Canon HS100 OCT or Optovue RTVue XR devices. Because the Canon HS100 OCT device is investigational (not yet FDA-approved), all of its side effects may not be known. There may be rare and unknown side effects. You must tell the study doctor and staff if you experience any side effects. If you are not honest about your side effects, it may not be safe for you to be in the study.
Source 1
IN THE STUDY. Part 1 (Cohorts 1-6) Payment Part 2 (Cohorts 7, 8, 9, and 10) Payment
Source 1
IN THE STUDY. I have read this consent form. I understand the purpose, procedures and risks as explained in this document. My questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I know that I can stop participation at any time. I will be given a signed and dated copy of this agreement. Name of Study Subject (printed) Signature of Study Subject Date Name of Study Subject’s Partner (printed) – if applicable Signature of Study Subject’s Partner – if applicable Date I have discussed the research study with the subject and subject’s partner and explained to them in non-technical terms all of the information contained in this informed consent form, including any risks that may reasonably be expected to occur. I further certify that I encouraged the subject and the subject’s partner to ask questions and that all questions asked were answered. Printed Name of Person Explaining Consent Form Signature of Person Explaining Consent Form Date You will be given a signed and dated copy of this informed consent to keep.‌
Source 1
IN THE STUDY. The overall experience of the xxx.xx app enables users to earn points through their actions in the app. Points will be collected on an ongoing basis by the participant within the app. Cumulative points for this study will be 25,000 points (collected after the participant completes all study required procedures, including the final survey). Participants in this study who complete all the actions can convert these total 25,000 points to a one-time only Xxxxxx.xxx gift card of up to $250.00 in value through the link provided after the final survey. You will be offered a phone stand approximately $10 in value, if you need it. If you are invited to do the usability interview and complete the interview successfully, you will receive a one-time link for a total of $50, redeemable as a one-time Xxxxxx.xxx gift card. The principal investigator is an employee of xxx.xx on whose app this study is being conducted and is being paid by the sponsor to conduct this research study.
Source 1

Related to IN THE STUDY

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development and Commercialization 8.01. CORPORATION undertakes to use continuous reasonable diligence to make and sell Licensed Products, including but not limited to, the performance of all efficacy, pharmaceutical, safety, toxicological and clinical tests, trials and studies and all other activities necessary in order to obtain the approval of the FDA for the production, use and sale of the Licensed Products, all as set forth in the Development Plan (annexed hereto as Appendix III and which is an integral part of this Agreement) and within all timetables set forth therein. CORPORATION further undertakes to exercise due diligence and to employ its reasonable diligence to obtain, the appropriate approvals of the health authorities for the production, use and sale of the Licensed Products, in each of the other countries of the world in which CORPORATION intend to produce, use, and/or sell Licensed Products. 8.02. Provided that applicable laws, rules and regulations require that the performance of the tests, trials, studies and other activities specified in Paragraph 8.01 above shall be carried out in accordance with FDA Good Laboratory Practices and in a manner acceptable to the relevant health authorities, CORPORATION shall carry out such tests, trials, studies and other activities in accordance with FDA Good Laboratory Practices and in a manner acceptable to the relevant health authorities. Furthermore, the Licensed Products shall be produced in accordance with FDA Good Manufacturing Practice (“GMP”) procedures in a facility which has been certified by the FDA as complying with GMP, provided that applicable laws, rules and regulations so require. 8.03. CORPORATION undertakes to begin the regular commercial production, use, and sale of the Licensed Products in good faith in accordance with the Development Plan and to continue diligently thereafter to commercialize the Licensed Products. 8.04. CORPORATION shall provide NYU with written annual reports on all activities and actions undertaken by CORPORATION to develop and commercialize the Licensed Products; such reports shall be made within sixty (60) days after each June 30th for the duration of this Agreement. 8.05. If CORPORATION shall not commercialize the Licensed Products within a reasonable time frame, unless such delay is necessitated by FDA or other regulatory agencies or unless NYU and CORPORATION have mutually agreed to amend the Development Plan because of unforeseen circumstances, NYU shall notify CORPORATION in writing of CORPORATION’s failure to commercialize and shall allow CORPORATION sixty (60) days to cure its failure to commercialize. CORPORATION’s failure to cure such delay to NYU’s reasonable satisfaction within such 60-day period shall be a material breach of this Agreement.

  • Development Program RWJPRI shall be solely responsible for and have the exclusive right, at its discretion but in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the exclusive right to develop the PRODUCT through STAGES O, I, II and III and shall have the exclusive right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Commercialization BMS, its Affiliates and Sublicensees shall be entitled to continue to sell (but not to actively promote after the effective date of termination) any existing inventory of Products in each terminated Region of the Territory for which Regulatory Approval and all pricing and reimbursement approvals therefor have been obtained (provided that such Products shall have launched in each such terminated country as of the applicable effective date of termination), in accordance with the terms and conditions of this Agreement, for a period not to exceed [***] from the effective date of such termination (the “Commercialization Wind-Down Period”). Any Products sold or disposed of by BMS, its Affiliates or Sublicensees during the Commercialization Wind-Down Period shall be subject to the same Total Compensation under Section 8.5 as would have applied had this Agreement otherwise remained in force and effect with respect to such terminated Product(s) and terminated Region(s). After the Commercialization Wind-Down Period, BMS, its Affiliates and Sublicensees shall not sell such terminated Products in such terminated Region(s) or make any representation regarding BMS’s status as a licensee of such Product in such Region(s). Either (i) at the request of BN at the end of the Commercialization Wind-Down Period or (ii) prior to the end of the Commercialization Wind-Down Period, if BN has assumed responsibilities for regulatory activities under the Regulatory Approval, has received all clearances and Regulatory Approvals needed to sell and import the terminated Product in a given terminated country, and provides written notice to BMS that it wishes to assume sale of the terminated Product in a terminated country, then, in either case (i) or (ii), at BN’s election, BMS shall sell and transfer to BN such portion of the terminated Product inventory then held by BMS or its Affiliates which is in a saleable condition (including that it is undamaged, has been stored in proper conditions and has no less than [***] shelf-life remaining) as had been allocated to the terminated Region(s) [***]. This Section 12.7(b) shall not apply in the case of termination by BMS under Section 12.2(b) based on Safety Reasons.

  • Field Trips Orange COUNTY funds may not be used to support any overnight and/or out of Central Florida travel, unless approved by the COUNTY’S Manager of the CCC or designee in advance. The AGENCY must have on file for field trip(s) that each participant, adult or minor, must have a signed release of liability form releasing the COUNTY from any liability. If the participant is a minor, the release must be signed by a parent/guardian. Central Florida is defined as Orange, Osceola, Seminole, Brevard, Lake, Polk, and Volusia Counties.